Online Enquiry
Subscribe
Log in / New User
Retrieve Password
此页面上的内容需要较新版本的 Adobe Flash Player。
切换导航
Home
Pharma China Web Edition
Pharma China Archives
Online Databases
Subscription/Download
Event Calendar
China Pharma Providers
About Us
Location:
Home
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Feature articles
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
Full Text
Title
Subscribe to Pharma China
Online Enquiry
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
ONLINE ENQUIRY
WiCON International Group
Bellevue, WA 98007, USA
info@pharmachinaonline.com
WiCON International Co. Ltd.
Osaka, Japan
info@pharmachinaonline.com
Relate News
2/23/2023
Chinese Mental Health Improved Last Year Although Prevalence in Youths...
2/20/2023
Clover, Adimmune Tie Up to Commercialize Quadrivalent Seasonal Flu Vac...
2/14/2023
Chinese Drugmakers Start 2023 with a Renewed Influx of Capital (Pharma...
2/13/2023
Nona Biosciences Enters into HCAb Based Antibody Discovery Collaborati...
2/13/2023
Corbus Licenses Clinical Stage Nectin-4 Targeting ADC from CSPC Megal...
2/9/2023
Facing Multiple Challenges, What Are the Clinical Development Trends i...
2/1/2023
In-Licensing Plummeted Sharply While Out-Licensing Skyrocketed in Chin...
1/20/2023
Funding for Biopharmaceuticals Plummeted in 2022 with Investments Flow...
1/17/2023
Sinovent Pharma Sign Two Out-licensing Deals with METiS and AmMax Bio
1/16/2023
NMPA Announces Package Insert Revision of Sodium Carbosulfate Formulat...
1/16/2023
CARsgen Thera and Huadong Medicine Forms Commercialization Partnership...
1/13/2023
NHC Issues 2nd Batch of the List of Drugs Subject To Focused State Rat...
1/10/2023
AmMax and Evopoint Enter into an Exclusive Option Agreement to License...
1/9/2023
NMPA Announces Package Insert Revision of Ibandronate Sodium Inj and T...
1/5/2023
Adcendo ApS Announces License Agreement with Duality Biologics on Next...
1/5/2023
FDA's Wang Yaning: Anti-Aβ Therapies Can Delay Progression of AD (Pha...
12/29/2022
NMPA Announces Package Insert Revision of Prednisolone Inj, Pethidine ...
12/26/2022
Two Large Out-licensing Deals Edge November Deal Values to Over $2.9B ...
12/22/2022
Merck and Kelun Ink Exclusive License Pact for Seven Investigational ...
12/19/2022
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4...
12/13/2022
Financing Rebounds for Chinese Drugmakers in November
12/8/2022
November Sees Several Approvals for China-developed Drugs (PharmaDJ)
12/1/2022
A Growing Number of Drugmakers in China Are on A Quest to Treat NASH (...
11/29/2022
A Slow October Sees Deals in Novel Therapies with New Technologies (Ph...
11/28/2022
Biocytogen Enters into Antibody Agreement with ADC Therapeutics
11/26/2022
CAR-T Therapies See New Competitors Emerge in October (PharmaDJ)
11/24/2022
China Issues the National Action Plan for Containment of Microbiologic...
11/23/2022
Fibrogen Sues Andao / Kind Pharma and Two Ex-employees for Stolen Pate...
11/17/2022
Mirati Therapeutics Sues China's InventisBio for CNY 99M in Trade Sec...
11/14/2022
Fundraising Continued to Drop in October, No Drugmaker Raised More Tha...
Page:
4
/
25
Total number of articles:
748
:
[First]
[<<]
[2]
[3]
[4]
[5]
[6]
[>>]
[End]
News
The Market
Industry News
Regulatory News
General Health
Legal/IPR News
Product/R&D News
API/Bulk Drug News
People in the News
Other News
Top News Worldwide
FEATURE ARTICLES
Editorials
Commentaries
Expert Opinions
Interviews
Case Studies
Company Profiles
Editor's Picks
GENERAL INFORMATION
TERMS & CONDITIONS OF USE
Download Info
Contact Us
Site map
|
Contact Us
|
Links
© Wicon International Group
×
Join the mailing list
We will e-mail you the most critical news and developments about China's healthcare sector, in real time and absolutely free.
name:
e-mail:
company:
submit